Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.
The effect of thymic substances on T circulating cells of patients treated for Hodgkin's disease.
J Biol Regul Homeost Agents. 1988 Oct-Dec;2(4):193-8. Unique Identifier : AIDSLINE MED/89269740 Chisesi T; Capnist G; Rancan L; Pellizzari G; Vespignani M; Department of Hematology, S. Bortolo Hospital, Vicenza, Italy.
Abstract:
Forty-one patients with Hodgkin's disease staged as IA(4), IIA/B(4/6) IIIA/B(6/9) and IVA/B(3/9) who had had radiotherapy (subtotal nodal irradiation (STNI) or total nodal irradiation (TNI), or combined one (STNI/TNI plus chemotherapy MOPP or MOPP/ABVD) have been enrolled consequently and randomized to receive thymic hormone (17 patients) or pentapeptide treatment (14 patients) for 3-6 months at the end of the therapeutic regimens. In all patients severe immunodeficiency evaluated either as leukopenia (WBC less than 4000/mm3) or lymphocytopenia (lymphocytes less than 1500/mm3) or CD3 and CD2 cell reduction, or imbalance of helper/suppressor (H/S) ratio have been documented before starting thymic therapy. Different results by immunorestorative therapy have been registered according to the entity of immunodeficiency. In fact in the group of 15 patients with severe lymphopenia (lymphocytes less than 1000/mm3) either the thymic hormone or the synthetic drug produced a significant increase of all subsets examined: CD3-CD2-CD4-CD8 without or with minimal influence on H/S ratio, due to the increase of absolute lymphocytes count. In the remaining patients with mild or no lymphopenia the two drugs resulted ineffective on T cells. Comparing the overall group of patients who received thymic therapy with a control group of patients who did not, an advantage in terms of recruitment of T cell compartment has been observed in the former group when mean values are compared. According to the clinical impact of the immunotherapy with thymic substances on these patients, a significant decrease in incidence of herpes virus infection (HVI) has been observed in patients who had had thymic therapy compared with the incidence of HVI in the control group (18% versus 53.8%).(ABSTRACT TRUNCATED AT 250 WORDS)
Keywords: Antineoplastic Agents/ADVERSE EFFECTS/THERAPEUTIC USE Clinical Trials Comparative Study Hodgkin's Disease/DRUG THERAPY/*IMMUNOLOGY Human Leukocyte Count/DRUG EFFECTS Lymphopenia/CHEMICALLY INDUCED/DRUG THERAPY Peptide Fragments/PHARMACOLOGY Random Allocation T-Lymphocytes/*DRUG EFFECTS Thymopoietins/PHARMACOLOGY Thymus Extracts/PHARMACOLOGY Thymus Hormones/*PHARMACOLOGY CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.
